Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane

Abstract

Data in this study show that in patients with osteosarcoma treated with doxorubicin alone or combined with dexrazoxane, the LV systolic function, as assessed by the fractional percentage of systolic shortening mean, showed a better performance in the group that received dexrazoxane. On the other hand, the occurrence of systolic dysfunction was similar in both groups.

Primary prevention of cardiotoxicity in paediatric cancer patients receiving anthracyclines: systematic review and meta-analysis of efficacy and safety profiles

“…Only prospective randomised and non-randomised controlled trials were included. Eleven trials administered dexrazoxane [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] , two trials administered the angiotensin converting enzyme inhibitor enalapril 26,27 , one trial administered the beta-blocker carvedilol 24 , one omega 3 fatty acids 28 , one coenzyme Q10 29 , one amifostine 30 , one silymarin 31 and one black seed oil 32 . Key trial characteristics of included trials are detailed in Table 1.…”

“…Sixteen reports of 11 trials administered dexrazoxane to paediatric patients receiving anthracyclines [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] . A total of 1333 paediatric patients receiving anthracyclines were included in meta-analysis of the cardioprotective effect of dexrazoxane in reducing the risk of developing significant systolic dysfunction.…”

Letter by Lipshultz Regarding Article, “Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?”

“…For more than a decade, children in Brazil and other South and Central American countries have received dexrazoxane. 7,8 Patients in Mexico have also received dexraxozane. 9,10 Similarly, for children in South Korea 11,12 and Canada, dexrazoxane has been available for many years.…”